๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity โ—† Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing โ—† Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich โ—† Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery โ—† Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity โ—† Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing โ—† Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich โ—† Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery โ—† Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—†
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Clayton
Clinical trial register · Australia

Clinical Trials in Clayton, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Clayton 19 Melbourne 18 South Brisbane 18 Kogarah 12 Heidelberg 12
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Clayton

19 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845Ovarian Cancer
AbbVie
Phase 2
400
Kogarah, Sydney, Auchenflower, Adelaide, Hobart, Clayton, Geelong, Melbourne
2025-11-13
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
AbbVie
Phase 2
110
Blacktown, Lambton Heights, Brisbane, Chermside, Ballarat, Clayton, Nedlands
2025-05-28
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
AbbVie
Phase 3
110
Randwick, Westmead, South Brisbane, Clayton, Perth
2024-08-08
Active, closed
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
AbbVie
Phase 2
108
Blacktown, Lambton Heights, Clayton
2024-07-29
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Kogarah, Liverpool, Waratah, Woolloongabba, Clayton, Fitzroy Melbourne, Melbourne
2024-05-19
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Blacktown, Macquarie University, South Brisbane, Kurralta Park, Woodville South, Clayton, Melbourne
2024-02-19
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
AbbVie
Phase 3
1,014
Botany, Concord, Darlinghurst, Tiwi, Woodville, Camberwell, Clayton, Victoria Park
2023-07-25
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Bankstown, Orange, Clayton, Melbourne
2023-04-04
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Westmead, Southport, Ballarat, Clayton, Malvern, Melbourne, Richmond, Subiaco
2023-03-15
Active, closed
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02966756Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
AbbVie
Phase 2
66
Concord, Kogarah, Clayton
2017-10-12
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
AbbVie
Phase 3
950
Macquarie University, South Brisbane, Southport, Clayton, Fitzroy Melbourne, Murdoch
2017-01-31
Rows per page Showing 1–19 of 19
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-australia/city/clayton

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 19 of those studies with a site in Clayton that also match the filters currently applied.

How many clinical trials are recruiting in Clayton?

7 of the 19 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Clayton), 19 studies
PhaseStudiesRecruitingShare
Phase 311457.9%
Phase 24221.1%
Phase 13115.8%
Observational105.3%

Most active sponsors

Lead sponsors with the most studies (Clayton)
Lead sponsorStudiesRecruiting
AbbVie197
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.